Trials / Completed
CompletedNCT03737565
Evaluation of the Safety and Efficacy of Titanium-nitric Oxide-coated Stent (Optimax®) in Patients With Lesions With a Low Risk of Restenosis (Diameter ≥ 3.0 mm and Length ≤ 20 mm)
Prospective, Multicenter and Observational Registry for the Evaluation of the Safety and Efficacy of Titanium-nitric Oxide-coated Stent (Optimax®) in Patients With Lesions With a Low Risk of Restenosis (Diameter ≥ 3.0 mm and Length ≤ 20 mm) (Reto 320 Study)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 350 (actual)
- Sponsor
- Fundación EPIC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This prospective registry is intended to evaluate the safety and efficacy of the Optimax® stent.
Detailed description
This prospective registry is intended to evaluate the safety and efficacy of the Optimax® stent in de novo coronary lesions with reference diameter ≥ 3.0 mm and Length ≤ 20 mm.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Optimax stent® | Percutaneous coronary intervention with Optimax stent® |
Timeline
- Start date
- 2019-02-17
- Primary completion
- 2025-01-02
- Completion
- 2025-01-02
- First posted
- 2018-11-09
- Last updated
- 2025-06-15
Locations
5 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT03737565. Inclusion in this directory is not an endorsement.